In addition, we analyzed the prognostic factors of stage II-IVb nasopharyngeal carcinoma patients treated at the Sun Yat-sen University Cancer Center with concurrent anti-EGFR targeted therapy to confirm the findings from the matching cohort. Here, EGFR is linked to nasopharyngeal carcinoma.